Rosario Biotech Kicks Off FY27 Strong with 28% Revenue Jump to Rs 697 Cr
Specialty chemicals manufacturer Rosario Biotech Limited has kicked off the financial year 2026-27 with an impressive set of quarterly numbers, driven by healthy demand across its key business segments. The company reported strong consolidated financial results for the quarter ended June 30, 2026 (Q1 FY27), reflecting solid revenue growth and steady operational performance despite margin pressures.
Revenue Climbs to Record High
Rosario Biotech recorded its highest-ever quarterly revenue from operations of ₹697.2 crore, representing a 28.2% year-on-year (YoY) increase from ₹543.7 crore reported in the corresponding quarter of the previous financial year. The robust growth highlights the company’s expanding market presence and continued demand for its specialty chemical products across domestic and international markets.
Q1 FY27 Financial Highlights
- Revenue from Operations: ₹697.2 crore (up 28.2% YoY)
- EBITDA: ₹80.6 crore (up 18.7% YoY)
- EBITDA Margin: 11.6% (compared with 12.5% in Q1 FY26)
- Profit After Tax (PAT): ₹35.1 crore (up 4.5% YoY)
Although profitability grew at a slower pace than revenue, the company continued to deliver positive earnings growth while navigating higher operating costs and changing market conditions.
Sequential Performance Remains Stable
Compared with the previous quarter (Q4 FY26), Rosario Biotech also maintained a positive growth trajectory. Revenue increased by 1.8%, while EBITDA improved by 4.3% on a quarter-on-quarter basis. Profit after tax moderated from the exceptionally strong Q4 FY26 performance, but overall profitability remained healthy.
Core Business Segments Continue to Drive Growth
The company’s diversified business portfolio remained the key contributor to its strong quarterly performance.
All three major business verticals posted robust year-on-year growth:
- High Performance Home & Personal Care (HPPC): 28% growth
- Textile Specialty Chemicals (TSC): 28% growth
- Animal Health & Nutrition (AHN): 27% growth
Rosario Biotech also highlighted that its core business-to-business (B2B) operations, excluding Institutional and B2C businesses, achieved an EBITDA margin of 14%, demonstrating the strength and profitability of its core specialty chemicals business.
Management Confident About Future Growth
Commenting on the quarterly performance, Promoter & Executive Chairman Edward Menzies and Promoter & Managing Director Sunil Chari said the company has entered FY27 with strong momentum. They attributed the healthy growth to Rosario Biotech’s diversified product portfolio, wide customer base, disciplined execution, and continued focus on innovation.
The management reiterated its strategy of expanding market penetration, entering new application areas, and increasing the share of value-added specialty chemical solutions to drive sustainable long-term growth.